 Antiprotozoal Agents
"Antiprotozoal Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that are destructive to protozoans.
| Descriptor ID |
D000981
|
| MeSH Number(s) |
D27.505.954.122.250.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antiprotozoal Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiprotozoal Agents".
This graph shows the total number of publications written about "Antiprotozoal Agents" by people in this website by year, and whether "Antiprotozoal Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 3 | 1 | 4 | | 2007 | 1 | 1 | 2 | | 2008 | 2 | 0 | 2 | | 2009 | 1 | 0 | 1 | | 2010 | 0 | 2 | 2 | | 2011 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 2 | 0 | 2 | | 2017 | 1 | 0 | 1 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antiprotozoal Agents" by people in Profiles.
-
Gómez Marín JE, El Bissati K. Editorial: Innovative Therapeutic and Immunomodulatory Strategies for Protozoan Infections. Front Cell Infect Microbiol. 2019; 9:293.
-
Berger BA, Cossio A, Saravia NG, Castro MDM, Prada S, Bartlett AH, Pho MT. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis. PLoS Negl Trop Dis. 2017 04; 11(4):e0005459.
-
Afanador GA, Muench SP, McPhillie M, Fomovska A, Schön A, Zhou Y, Cheng G, Stec J, Freundlich JS, Shieh HM, Anderson JW, Jacobus DP, Fidock DA, Kozikowski AP, Fishwick CW, Rice DW, Freire E, McLeod R, Prigge ST. Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay. Biochemistry. 2013 Dec 23; 52(51):9155-66.
-
Stec J, Fomovska A, Afanador GA, Muench SP, Zhou Y, Lai BS, El Bissati K, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Sommervile C, Woods S, Roberts CW, Rice D, Prigge ST, McLeod R, Kozikowski AP. Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii. ChemMedChem. 2013 Jul; 8(7):1138-60.
-
Fomovska A, Huang Q, El Bissati K, Mui EJ, Witola WH, Cheng G, Zhou Y, Sommerville C, Roberts CW, Bettis S, Prigge ST, Afanador GA, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Pieroni M, Stec J, Muench SP, Rice DW, Kozikowski AP, McLeod R. Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. Antimicrob Agents Chemother. 2012 May; 56(5):2666-82.
-
Kortagere S, Mui E, McLeod R, Welsh WJ. Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach. J Comput Aided Mol Des. 2011 May; 25(5):403-11.
-
Nguyen TH, Weisenthal RW, Florakis GJ, Reidy JJ, Gaster RN, Tom D. Penetrating keratoplasty in active Acanthamoeba keratitis. Cornea. 2010 Sep; 29(9):1000-4.
-
Tanhehco T, Colby K. The clinical experience of Acanthamoeba keratitis at a tertiary care eye hospital. Cornea. 2010 Sep; 29(9):1005-10.
-
McLeod R, Kieffer F, Sautter M, Hosten T, Pelloux H. Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz. 2009 Mar; 104(2):320-44.
-
Benevento JD, Jager RD, Noble AG, Latkany P, Mieler WF, Sautter M, Meyers S, Mets M, Grassi MA, Rabiah P, Boyer K, Swisher C, McLeod R. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol. 2008 Aug; 126(8):1152-6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|